isopharm limited
isopharm limited Company Information
Company Number
03843619
Website
www.isopharm.co.ukRegistered Address
unit 18 jessops riverside, 800 brightside lane, sheffield, S9 2RX
Industry
Manufacture of medical and dental instruments and supplies
Telephone
01709525256
Next Accounts Due
December 2024
Group Structure
View All
Shareholders
agilo software bidco limited 100%
isopharm limited Estimated Valuation
Pomanda estimates the enterprise value of ISOPHARM LIMITED at £6m based on a Turnover of £5.6m and 1.08x industry multiple (adjusted for size and gross margin).
isopharm limited Estimated Valuation
Pomanda estimates the enterprise value of ISOPHARM LIMITED at £0 based on an EBITDA of £-197k and a 6.28x industry multiple (adjusted for size and gross margin).
isopharm limited Estimated Valuation
Pomanda estimates the enterprise value of ISOPHARM LIMITED at £1.4m based on Net Assets of £648k and 2.21x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Isopharm Limited Overview
Isopharm Limited is a live company located in sheffield, S9 2RX with a Companies House number of 03843619. It operates in the manufacture of medical and dental instruments and supplies sector, SIC Code 32500. Founded in September 1999, it's largest shareholder is agilo software bidco limited with a 100% stake. Isopharm Limited is a mature, mid sized company, Pomanda has estimated its turnover at £5.6m with unknown growth in recent years.
Upgrade for unlimited company reports & a free credit check
Isopharm Limited Health Check
Pomanda's financial health check has awarded Isopharm Limited a 2 rating. We use a traffic light system to show it exceeds the industry average on 1 measures and has 5 areas for improvement. Company Health Check FAQs
1 Strong
5 Regular
5 Weak
Size
annual sales of £5.6m, make it smaller than the average company (£16.4m)
£5.6m - Isopharm Limited
£16.4m - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Isopharm Limited
- - Industry AVG
Production
with a gross margin of 39.3%, this company has a comparable cost of product (38.2%)
39.3% - Isopharm Limited
38.2% - Industry AVG
Profitability
an operating margin of -7.9% make it less profitable than the average company (6.3%)
-7.9% - Isopharm Limited
6.3% - Industry AVG
Employees
with 57 employees, this is below the industry average (87)
57 - Isopharm Limited
87 - Industry AVG
Pay Structure
on an average salary of £37.2k, the company has an equivalent pay structure (£45.2k)
£37.2k - Isopharm Limited
£45.2k - Industry AVG
Efficiency
resulting in sales per employee of £97.6k, this is less efficient (£173.4k)
£97.6k - Isopharm Limited
£173.4k - Industry AVG
Debtor Days
it gets paid by customers after 57 days, this is near the average (48 days)
57 days - Isopharm Limited
48 days - Industry AVG
Creditor Days
its suppliers are paid after 39 days, this is close to average (39 days)
39 days - Isopharm Limited
39 days - Industry AVG
Stock Days
it holds stock equivalent to 46 days, this is less than average (98 days)
46 days - Isopharm Limited
98 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 17 weeks, this is average cash available to meet short term requirements (15 weeks)
17 weeks - Isopharm Limited
15 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 73.8%, this is a higher level of debt than the average (43.1%)
73.8% - Isopharm Limited
43.1% - Industry AVG
ISOPHARM LIMITED financials
Isopharm Limited's latest turnover from March 2023 is £5.6 million and the company has net assets of £648 thousand. According to their latest financial statements, Isopharm Limited has 57 employees and maintains cash reserves of £608 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2023 | Mar 2022 | Mar 2021 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 5,565,000 | 5,356,000 | 5,771,000 | 3,810,000 | ||||||||||
| Other Income Or Grants | 0 | 0 | 0 | 0 | ||||||||||
| Cost Of Sales | 3,377,000 | 2,928,000 | 3,131,000 | 1,634,000 | ||||||||||
| Gross Profit | 2,188,000 | 2,428,000 | 2,640,000 | 2,176,000 | ||||||||||
| Admin Expenses | 2,626,000 | 1,910,000 | 2,459,000 | 1,905,000 | ||||||||||
| Operating Profit | -438,000 | 518,000 | 181,000 | 271,000 | ||||||||||
| Interest Payable | 0 | 0 | 6,000 | 5,000 | ||||||||||
| Interest Receivable | 1,000 | 0 | 0 | 1,000 | ||||||||||
| Pre-Tax Profit | -437,000 | 518,000 | 175,000 | 267,000 | ||||||||||
| Tax | -25,000 | 60,000 | 29,000 | -96,000 | ||||||||||
| Profit After Tax | -462,000 | 578,000 | 204,000 | 171,000 | ||||||||||
| Dividends Paid | 0 | 0 | 16,000 | 51,000 | ||||||||||
| Retained Profit | -462,000 | 578,000 | 188,000 | 120,000 | ||||||||||
| Employee Costs | 2,120,000 | 1,621,000 | 1,916,000 | 946,000 | ||||||||||
| Number Of Employees | 57 | 50 | 44 | 36 | 29 | 20 | 18 | 15 | ||||||
| EBITDA* | -197,000 | 815,000 | 535,000 | 491,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2023 | Mar 2022 | Mar 2021 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 183,000 | 477,000 | 97,000 | 431,000 | 344,289 | 356,346 | 136,529 | 109,931 | 27,728 | 47,785 | 54,362 | 3,660 | 5,698 | 5,141 |
| Intangible Assets | 0 | 0 | 386,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 183,000 | 477,000 | 483,000 | 431,000 | 344,289 | 356,346 | 136,529 | 109,931 | 27,728 | 47,785 | 54,362 | 3,660 | 5,698 | 5,141 |
| Stock & work in progress | 427,000 | 316,000 | 289,000 | 322,000 | 304,346 | 357,100 | 206,881 | 243,463 | 172,041 | 175,993 | 135,464 | 98,147 | 87,850 | 89,138 |
| Trade Debtors | 879,000 | 522,000 | 569,000 | 461,000 | 388,097 | 327,932 | 313,491 | 288,298 | 25,335 | 30,079 | 33,034 | 229,419 | 247,851 | 310,301 |
| Group Debtors | 283,000 | 675,000 | 675,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 97,000 | 70,000 | 124,000 | 97,000 | 35,312 | 27,549 | 32,061 | 37,054 | 302,699 | 248,347 | 202,529 | 0 | 21,542 | 15,305 |
| Cash | 608,000 | 754,000 | 469,000 | 444,000 | 385,322 | 199,016 | 222,205 | 116,719 | 90,831 | 66,961 | 49,772 | 10,761 | 50,426 | 139,036 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 2,294,000 | 2,337,000 | 2,126,000 | 1,324,000 | 1,113,077 | 911,597 | 774,638 | 685,534 | 590,906 | 521,380 | 420,799 | 338,327 | 407,669 | 553,780 |
| total assets | 2,477,000 | 2,814,000 | 2,609,000 | 1,755,000 | 1,457,366 | 1,267,943 | 911,167 | 795,465 | 618,634 | 569,165 | 475,161 | 341,987 | 413,367 | 558,921 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 361,000 | 221,000 | 372,000 | 305,000 | 246,570 | 404,176 | 303,363 | 276,728 | 457,805 | 410,570 | 329,606 | 271,737 | 308,951 | 435,041 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 83,133 | 93,089 | 29,056 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 27,000 | 26,920 | 26,919 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 1,468,000 | 1,483,000 | 1,670,000 | 1,026,000 | 317,081 | 174,907 | 148,119 | 172,574 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current liabilities | 1,829,000 | 1,704,000 | 2,042,000 | 1,358,000 | 673,704 | 699,091 | 480,538 | 449,302 | 457,805 | 410,570 | 329,606 | 271,737 | 308,951 | 435,041 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 7,000 | 33,350 | 60,268 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12,026 | 32,981 | 0 | 34,166 | 53,630 |
| provisions | 0 | 0 | 35,000 | 64,000 | 44,706 | 41,583 | 21,590 | 18,976 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 0 | 0 | 35,000 | 71,000 | 78,056 | 101,851 | 21,590 | 18,976 | 0 | 12,026 | 32,981 | 0 | 34,166 | 53,630 |
| total liabilities | 1,829,000 | 1,704,000 | 2,077,000 | 1,429,000 | 751,760 | 800,942 | 502,128 | 468,278 | 457,805 | 422,596 | 362,587 | 271,737 | 343,117 | 488,671 |
| net assets | 648,000 | 1,110,000 | 532,000 | 326,000 | 705,606 | 467,001 | 409,039 | 327,187 | 160,829 | 146,569 | 112,574 | 70,250 | 70,250 | 70,250 |
| total shareholders funds | 648,000 | 1,110,000 | 532,000 | 326,000 | 705,606 | 467,001 | 409,039 | 327,187 | 160,829 | 146,569 | 112,574 | 70,250 | 70,250 | 70,250 |
| Mar 2023 | Mar 2022 | Mar 2021 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||
| Operating Profit | -438,000 | 518,000 | 181,000 | 271,000 | ||||||||||
| Depreciation | 241,000 | 297,000 | 354,000 | 220,000 | 3,885 | 1,766 | 2,501 | 27,104 | 26,319 | 22,593 | 6,763 | 2,824 | 1,826 | 9,179 |
| Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 43,605 |
| Tax | -25,000 | 60,000 | 29,000 | -96,000 | ||||||||||
| Stock | 111,000 | 27,000 | 289,000 | 17,654 | -52,754 | 150,219 | -36,582 | 71,422 | -3,952 | 40,529 | 37,317 | 10,297 | 87,850 | 89,138 |
| Debtors | -8,000 | -101,000 | 1,368,000 | 134,591 | 67,928 | 9,929 | 20,200 | -2,682 | 49,608 | 42,863 | 6,144 | -39,974 | 269,393 | 325,606 |
| Creditors | 140,000 | -151,000 | 372,000 | 58,430 | -157,606 | 100,813 | 26,635 | -181,077 | 47,235 | 80,964 | 57,869 | -37,214 | 308,951 | 435,041 |
| Accruals and Deferred Income | -15,000 | -187,000 | 1,670,000 | 708,919 | 142,174 | 26,788 | -24,455 | 172,574 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes & Provisions | 0 | -35,000 | 35,000 | 19,294 | 3,123 | 19,993 | 2,614 | 18,976 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | -200,000 | 576,000 | 984,000 | 1,029,398 | ||||||||||
| Investing Activities | ||||||||||||||
| capital expenditure | ||||||||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | ||||||||||||||
| Financing Activities | ||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | -83,133 | -9,956 | 64,033 | 29,056 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | -26,270 | -26,917 | 87,187 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -12,026 | -20,955 | 32,981 | -34,166 | 34,166 | 53,630 |
| share issue | ||||||||||||||
| interest | 1,000 | 0 | -6,000 | -4,000 | ||||||||||
| cash flow from financing | 1,000 | 0 | 338,000 | -613,009 | ||||||||||
| cash and cash equivalents | ||||||||||||||
| cash | -146,000 | 285,000 | 469,000 | 58,678 | 186,306 | -23,189 | 105,486 | 25,888 | 23,870 | 17,189 | 39,011 | -39,665 | 50,426 | 139,036 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | -146,000 | 285,000 | 469,000 | 58,678 | 186,306 | -23,189 | 105,486 | 25,888 | 23,870 | 17,189 | 39,011 | -39,665 | 50,426 | 139,036 |
isopharm limited Credit Report and Business Information
Isopharm Limited Competitor Analysis
Perform a competitor analysis for isopharm limited by selecting its closest rivals and benchmarking them against 12 key performance metrics.
isopharm limited Ownership
ISOPHARM LIMITED group structure
Isopharm Limited has no subsidiary companies.
Ultimate parent company
ISOPHARM LIMITED
03843619
isopharm limited directors
Isopharm Limited currently has 3 directors. The longest serving directors include Mr Paul Ward (Aug 2018) and Mr Neil Laycock (Jul 2023).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Paul Ward | United Kingdom | 47 years | Aug 2018 | - | Director |
| Mr Neil Laycock | England | 55 years | Jul 2023 | - | Director |
| Mr James Bodha | England | 57 years | Apr 2024 | - | Director |
P&L
March 2023turnover
5.6m
+4%
operating profit
-438k
-185%
gross margin
39.4%
-13.27%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2023net assets
648k
-0.42%
total assets
2.5m
-0.12%
cash
608k
-0.19%
net assets
Total assets minus all liabilities
Similar Companies
isopharm limited company details
company number
03843619
Type
Private limited with Share Capital
industry
32500 - Manufacture of medical and dental instruments and supplies
incorporation date
September 1999
age
25
accounts
Full Accounts
ultimate parent company
previous names
isopharm sentry limited (May 2013)
sentry products limited (February 2005)
incorporated
UK
address
unit 18 jessops riverside, 800 brightside lane, sheffield, S9 2RX
last accounts submitted
March 2023
isopharm limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 6 charges/mortgages relating to isopharm limited. Currently there are 0 open charges and 6 have been satisfied in the past.
isopharm limited Companies House Filings - See Documents
| date | description | view/download |
|---|
